This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weiner, L. M. Articles by de Palazzo, I. G. Search for Related Content PubMed PubMed Citation Articles by Weiner, L. M. Articles by de Palazzo, I. G.

A Human Tumor Xenograft Model of Therapy with a Bispecific Monoclonal Antibody Targeting c-erbB-2 and CD16¹

Departments of Medical Oncology [L. M. W., M. H., G. P. A., I. G. P.], Pharmacology [F. L.], and Biostatistics [P. W.], Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

New strategies are required to clinically exploit the ability of monoclonal antibodies to target tumor for lysis by cellular effector mechanisms. In this report we examine the therapeutic effects of 2B1, a bispecific monoclonal antibody with specificity for the extracellular domain of the c-erbB-2 oncogene product and the human Fc receptor, FcRIII (CD16), describe the characteristics and limitations of this model, and examine the mechanisms underlying the observed responses. The model uses SK-OV-3 human ovarian carcinoma xenografts in scid mice. These cells are susceptible to 2B1-directed lysis by human peripheral blood lymphocytes or lymphokine-activated killer cells, and maintain c-erbB-2 expression in vivo. ¹²⁵I-labeled 2B1 selectively accumulates in tumor, with a peak of 10.5% injected dose/g of tumor 24 h following its i.v. injection. However, the selectivity of this binding is lessened by 2B1 accumulation in the lungs and other normal organs and persistence in the blood. This is caused by antibody binding to murine lung, colon, stomach, and skin expressing the epitope recognized by the anti-c-erbB-2 component of 2B1 in tumor-bearing, but not normal mice. In treatment studies using various permutations of antibody, human peripheral blood lymphocytes or lymphokine-activated killer cells and interleukin 2, cellular therapy alone had minimal effects on SK-OV-3 xenograft growth, but significantly improved when 2B1 treatment was incorporated. Median survivals increased from 80 ± 3.5 days with no therapy to 131 ± 7.3 days following therapy with 100 µg 2B1, interleukin 2, and human peripheral blood lymphocytes, with 70% of animals exhibiting no evidence of tumor at day 150. These effects were preserved when the cells were administered in human serum. In contrast, human serum abolished the antitumor effects of 520C9, which is the parent anti-c-erbB-2 antibody of 2B1. Thus 2B1-based therapy has therapeutic effects, without obvious toxicity, despite the targeting of this antibody to normal murine tissues. Since combinations of 2B1 and interleukin 2 may have antitumor properties, mechanisms other than bispecific monoclonal antibody-promoted conjugation of c-erbB-2 antigen-expressing tumor to CD16-expressing effector cells may be involved.

¹ Supported by NIH Grant CA50633, the Frank Strick Foundation, and the Bernard A. and Rebecca S. Bernard Foundation.

² To whom requests for reprints should be addressed, at Department of Medical Oncology. Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111.

³ Present address: Brisol-Myers Squibb Pharmaceutical Research Institute, P. O. Box 4755, Syracuse, NY 13221-4755.

Received 7/28/92. Accepted 10/19/92.

This article has been cited by other articles:

				G. Behar, S. Siberil, A. Groulet, P. Chames, M. Pugniere, C. Boix, C. Sautes-Fridman, J.-L. Teillaud, and D. Baty Isolation and characterization of anti-Fc{gamma}RIII (CD16) llama single-domain antibodies that activate natural killer cells Protein Eng. Des. Sel., January 1, 2008; 21(1): 1 - 10. [Abstract] [Full Text] [PDF]

				L. S. Shahied, Y. Tang, R. K. Alpaugh, R. Somer, D. Greenspon, and L. M. Weiner Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format J. Biol. Chem., December 24, 2004; 279(52): 53907 - 53914. [Abstract] [Full Text] [PDF]

				R. Nahta and F. J. Esteva HER-2-Targeted Therapy: Lessons Learned and Future Directions Clin. Cancer Res., November 1, 2003; 9(14): 5078 - 5084. [Abstract] [Full Text] [PDF]

				R. Nahta, G. N. Hortobagyi, and F. J. Esteva Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention Oncologist, February 1, 2003; 8(1): 5 - 17. [Abstract] [Full Text] [PDF]

				A. M. McCall, L. Shahied, A. R. Amoroso, E. M. Horak, H. H. Simmons, U. Nielson, G. P. Adams, R. Schier, J. D. Marks, and L. M. Weiner Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity J. Immunol., May 15, 2001; 166(10): 6112 - 6117. [Abstract] [Full Text] [PDF]